What is Cepheid?
Headquartered in Sunnyvale, California, Cepheid operates at the intersection of biotechnology and automated engineering. Since its inception in 1996, the company has focused on the development, manufacturing, and commercialization of molecular systems that streamline complex genetic testing. By automating manual, labor-intensive procedures, Cepheid provides healthcare institutions with the tools necessary to perform rapid, accurate diagnostics for infectious organisms and genetic-based diseases. Its market position is defined by a commitment to accessibility, allowing facilities of varying sizes to integrate high-complexity testing into their standard clinical workflows, thereby improving patient outcomes and operational efficiency.
How much funding has Cepheid raised?
Cepheid has raised a total of $33M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$3.2M
Series B
$8.3M
Series C
$19.1M
Angel/Seed (1996): $2.5M with participation from Medtronic, Inc. and Advanced Technology Ventures
Series A (1997): $3.2M, investors not publicly disclosed
Series B (1998): $8.3M, investors not publicly disclosed
Series C (2000): $19.1M, investors not publicly disclosed
Key Investors in Cepheid
Medtronic, Inc.
Medtronic is a global healthcare technology company founded in 1949 that develops and manufactures medical devices, therapies, and digital health solutions. Its portfolio spans cardiovascular, neuroscience, medical surgical, and diabetes technologies.
Advanced Technology Ventures
Founded in 1979, Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with $1.4 billion in capital under management, focusing on healthcare, communications, and IT infrastructure.
Undisclosed Investors
What's next for Cepheid?
With the successful closure of this major strategic investment, Cepheid is well-positioned to accelerate its research and development pipeline. The company is expected to leverage this capital to enhance its existing suite of molecular diagnostic tests and explore new therapeutic areas where rapid genetic insights are critical. As the healthcare industry continues to prioritize precision medicine and decentralized testing, Cepheid's focus on scalable, automated solutions will likely remain a key driver of its long-term growth. Future strategic initiatives will likely involve deepening its footprint in international markets and fostering collaborative partnerships with global health organizations to address emerging diagnostic challenges.
See full Cepheid company page
